ul. Kukiełki 3A
02-207 Warszawa

+48 22 862 36 64
biuro@mededu.pl

Kategoria: OncoReview
Sortuj wg:
Domyślnie | Autor | Daty | Wyświetleń


OncoReview 2017; 3(27): 109-115.

Autorzy: Anna Nasierowska-Guttmejer

Streszczenie: 

Abstract: The following changes were introduced in 2017 WHO and TnM classifications: 1. a new group of well-differentiated neuroendocrine tumors with the proliferation index of more than 20% and mitotic count of 20 per 10 hpf (NET G3), formerly classified under neuroendocrine carcinomas (NEC G3) 2. the division of poorly differentiated neuroendocrine tumors (PD NET) with the Ki-67 index of more than 20% into two groups in terms of the degree of differentiation and prognosis: NET G3 and NEC. 3. the replacement of MANEC with MINEN within the mixed group 4. the verification of histological grading (G) criteria 5. new TNM staging criteria, based on ENETS guidelines.


Key words: neuroendocrine tumors, G3 NET, NEC, neuroendocrine carcinoma, Ki-67 proliferation index
Informacje o publikacji
Dodany 2017-12-19
DOI:
Wielkość 103.61 KB
Dodany przez Marcin Kuźma
Pobrany 502


OncoReview 2017; 2(26): 64-69

Autorzy: Sławomir Blamek

Streszczenie: 

Abstract: The number of patients with cardiac implantable electronic devices (CIEDs) constantly increases and due to growing incidence of cancer, many of them will require an anticancer treatment. At least a half of patients treated for malignant neoplasms, apart from other treatment methods, require radiotherapy.Although papers presenting the results of in vitro studies provide clues on the susceptibility of CIEDs to ionizing radiation, the research methods used often stand out from typical clinical situations.Direct irradiation of the devices is avoided and the doses delivered to pulse generators are far below those seen in the in vitro studies. In this review the most important clinical observations made during irradiation of patients with CIEDs are summarized and practical directions for physicians and physicists involved in radiation treatment planning and delivery are given.

Słowa kluczowe:

Key words: radiotherapy, cardiac implantable electronic device, pacemaker, implantable cardioverter- -defibrillator, cardiac resynchronization therapy
Informacje o publikacji
Dodany 2017-09-05
DOI:
Wielkość 89.17 KB
Dodany przez Marcin Kuźma
Pobrany 380


OncoReview 2017; 1(25): 44-48

Autorzy: Marek Kowalczyk, Michał Piątek, Dorota Imielska-Zdunek, Aleksandra Derra, Aleksandra Zemła, Agnieszka Boratyn-Nowicka

Streszczenie: 

Abstract: This article presents methods of effective treatment of primary metastatic nasopharyngeal carcinoma, both causative and symptomatic, taking into account possible available treatment therapies(chemotherapy, targeted therapy, radiotherapy), and includes a case report. The applied treatment allowed for satisfactory control of the disease and much higher overall survival than expected – the patient survived for 53 months from the initial diagnosis and 41 months from being diagnosed with metastatic carcinoma.

Słowa kluczowe:

Key words: nasopharyngeal carcinoma, strategy of treatment, systemic therapy
Informacje o publikacji
Dodany 2017-09-05
DOI:
Wielkość 106.33 KB
Dodany przez Marcin Kuźma
Pobrany 223


OncoReview 2017; 1(25): 32-37

Autorzy: Maria Kurowska, Joanna Malicka, Jerzy S. Tarach

Streszczenie: 

Abstract: Introduction: Acromegaly in the course of a pituitary microadenoma or neuroendocrine GHRH-secreting tumour (GHRH, growth hormone-releasing hormone) MRI invisible is very rare. Objective: To present the difficulties in determining the cause behind an excessive production of the growth hormone in a patient suffering from long-standing acromegaly, without a pituitary focal lesion that would be visible on MRI. Case report: The authors describe a case of a 69-year-old female with acromegaly, diagnosed 22 yearsearlier based on the typical somatic symptoms, and confirmed by the elevated concentration of insulin-like growth factor type 1 and lack of growth hormone suppression in the oral glucose tolerancetest. The initial MRI scan (1994) had revealed a hypoechogenic 2 x 3 mm lesion in the anterior lobe ofthe pituitary gland, whose presence was not reported in the subsequent MRI tests. As ectopic GHRH orgrowth hormone secretion was suspected, a neuroendocrine tumour was searched for. The 47.7 × 54× 35.7 mm tumour, located in the thoracic outlet, accumulating tektreotide in receptor scintigraphy,turned out to be a nodular goitre on histopathology. Due to the undetermined location of the source of growth hormone overproduction, failure to measure GHRH levels, and the patient’s lack of consentto undergo sella turcica exploration, long-acting release octreotide had been used for many years tomanage the patient’s condition.Summary: The long-lasting and ineffective search for a neuroendocrine tumour producing GHRH orgrowth hormone as well as the absence of a focal lesion in the repeated MRI scans render it impossibleto unequivocally determine the cause of the patient’s acromegaly, and illustrate the difficulties indiscovering the source of growth hormone overproduction. Summary: The long-lasting and ineffective search for a neuroendocrine tumour producing GHRH or growth hormone as well as the absence of a focal lesion in the repeated MRI scans render it impossible to unequivocally determine the cause of the patient’s acromegaly, and illustrate the difficulties in discovering the source of growth hormone overproduction. Summary: The long-lasting and ineffective search for a neuroendocrine tumour producing GHRH orgrowth hormone as well as the absence of a focal lesion in the repeated MRI scans render it impossibleto unequivocally determine the cause of the patient’s acromegaly, and illustrate the difficulties indiscovering the source of growth hormone overproduction. Summary: The long-lasting and ineffective search for a neuroendocrine tumour producing GHRH or growth hormone as well as the absence of a focal lesion in the repeated MRI scans render it impossible to unequivocally determine the cause of the patient’s acromegaly, and illustrate the difficulties in discovering the source of growth hormone overproduction.

Słowa kluczowe:

Key words: acromegaly, microadenoma, neuroendocrine tumour, ectopic GHRH secretion
Informacje o publikacji
Dodany 2017-09-05
DOI:
Wielkość 152.95 KB
Dodany przez Marcin Kuźma
Pobrany 183


OncoReview 2017; 1(25): 22-27

Autorzy: Agnieszka Kolasińska-Ćwikła

Streszczenie: 

Abstract: Neuroendocrine tumours are a rare and heterogeneous group of neoplasms. Most of the patients are diagnosed with locally advanced or metastatic disease and curative surgery is rarely an option.Somatostatin analogues have been shown to control the symptoms and growth of well-differentiated metastatic neuroendocrine tumours. Octreotide LAR is one of the treatment options.

Słowa kluczowe:

Key words: neuroendocrine tumours, somatostatin analogues, octreotide LAR
Informacje o publikacji
Dodany 2017-09-05
DOI:
Wielkość 85.71 KB
Dodany przez Marcin Kuźma
Pobrany 163